Caribou Biosciences, Inc. (NASDAQ:CRBU) Stock Has Average Price Target of $4.50 According to Analysts

Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) have been assigned an average recommendation of “Hold” from the seven research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $4.50.

A number of equities research analysts have issued reports on the stock. Brookline Capital Markets lowered shares of Caribou Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 7th. Bank of America decreased their price target on shares of Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, August 14th. HC Wainwright downgraded shares of Caribou Biosciences from a “buy” rating to a “neutral” rating in a research note on Thursday, October 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Thursday, October 15th. Finally, Royal Bank Of Canada lowered Caribou Biosciences from an “outperform” rating to a “sector perform” rating and set a $1.00 price objective on the stock. in a research report on Wednesday, October 7th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. CTC Alternative Strategies Ltd. acquired a new stake in Caribou Biosciences in the 1st quarter valued at about $29,000. Next Capital Management LLC purchased a new stake in shares of Caribou Biosciences during the second quarter worth approximately $35,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Caribou Biosciences during the second quarter worth approximately $41,000. Spark Investment Management LLC purchased a new stake in shares of Caribou Biosciences during the second quarter worth approximately $42,000. Finally, Sei Investments Co. acquired a new stake in Caribou Biosciences in the first quarter valued at approximately $59,000. 77.51% of the stock is owned by institutional investors and hedge funds.

Caribou Biosciences Price Performance

Shares of NASDAQ:CRBU opened at $0.41 on Friday. The firm has a market capitalization of $44.34 million, a PE ratio of -0.40 and a beta of 2.50. The firm’s 50-day moving average is $0.90 and its two-hundred day moving average is $1.59. Caribou Biosciences has a 1 year low of $0.39 and a 1 year high of $2.49.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.01. The business had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $1.60 million. Caribou Biosciences had a negative net margin of 1,085.00% and a negative return on equity of 102.74%. Analysts expect that Caribou Biosciences will post -0.94 EPS for the current fiscal year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc. is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses CRISPR gene-editing technology to engineer allogeneic, or “off-the-shelf,” immune-cell therapies designed to target cancer cells while reducing limitations associated with individualized cell treatments. Caribou’s research platform is based on CRISPR hybrid RNA-DNA guide technology, which is intended to support precise and efficient genome editing.